[go: up one dir, main page]

WO1996030523A3 - Antigen presentation system based on retrovirus-like particles - Google Patents

Antigen presentation system based on retrovirus-like particles Download PDF

Info

Publication number
WO1996030523A3
WO1996030523A3 PCT/EP1996/001433 EP9601433W WO9630523A3 WO 1996030523 A3 WO1996030523 A3 WO 1996030523A3 EP 9601433 W EP9601433 W EP 9601433W WO 9630523 A3 WO9630523 A3 WO 9630523A3
Authority
WO
WIPO (PCT)
Prior art keywords
particles
presentation system
antigen presentation
retrovirus
system based
Prior art date
Application number
PCT/EP1996/001433
Other languages
French (fr)
Other versions
WO1996030523A2 (en
Inventor
Hans Wolf
Ralf Wagner
Ludwig Deml
Klaus Osterrieder
Frank Notka
Original Assignee
Hans Wolf
Ralf Wagner
Ludwig Deml
Klaus Osterrieder
Frank Notka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hans Wolf, Ralf Wagner, Ludwig Deml, Klaus Osterrieder, Frank Notka filed Critical Hans Wolf
Priority to EP96911989A priority Critical patent/EP0817854A2/en
Publication of WO1996030523A2 publication Critical patent/WO1996030523A2/en
Publication of WO1996030523A3 publication Critical patent/WO1996030523A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to the provision of an antigen presentation system on the basis of a DNA sequence encoding a protein capable of self assembly into particles without a lipid membrane, preferably a retroviral group-specific antigen (gag) that can be used, e.g., for the preventive and therapeutic immunization of mammals against infectious diseases or neoplasias.
PCT/EP1996/001433 1995-03-31 1996-04-01 Antigen presentation system based on retrovirus-like particles WO1996030523A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP96911989A EP0817854A2 (en) 1995-03-31 1996-04-01 Antigen presentation system based on retrovirus-like particles

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP95104848 1995-03-31
EP95104850.3 1995-03-31
EP95104850 1995-03-31
EP95104849 1995-03-31
EP95104849.5 1995-03-31
EP95104848.7 1995-03-31

Publications (2)

Publication Number Publication Date
WO1996030523A2 WO1996030523A2 (en) 1996-10-03
WO1996030523A3 true WO1996030523A3 (en) 1997-04-17

Family

ID=27236505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/001433 WO1996030523A2 (en) 1995-03-31 1996-04-01 Antigen presentation system based on retrovirus-like particles

Country Status (3)

Country Link
EP (1) EP0817854A2 (en)
CN (1) CN1185811A (en)
WO (1) WO1996030523A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510960A (en) 1998-11-30 2010-04-08 サイトス バイオテクノロジー アーゲー Ordered molecular presentation of antigens, method of presentation and use
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7476517B2 (en) 1999-06-30 2009-01-13 Evotec Ag Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US20040014033A1 (en) 1999-06-30 2004-01-22 Evotec Biosystems Ag, A Corporation Of Germany Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
DE60034947T2 (en) * 1999-06-30 2008-01-24 Evotec Ag VIRUSUAL PARTICLES, PREPARATION AND USE IN SCREENING AND FUNCTIONAL GENOME APPLICATION
DE19957838C2 (en) 1999-11-25 2002-11-21 Pette Heinrich Inst Gene therapy of HIV-infected people through expression of membrane-anchored gp41 peptides
EP2388015A1 (en) * 2000-03-02 2011-11-23 Emory University DNA expression vectors and methods of use
AU2001252458A1 (en) 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
EP1219705B1 (en) * 2000-12-29 2007-11-28 Evotec AG Virus like particles, their preparation and their use preferably in pharmaceutical screening and functional genomics
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
EP2280074A3 (en) 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines
EP2196217A1 (en) 2001-09-14 2010-06-16 Cytos Biotechnology AG Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
MXPA04002644A (en) 2001-10-05 2004-07-08 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof.
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US7138252B2 (en) 2002-07-17 2006-11-21 Cytos Biotechnology Ag Molecular antigen arrays
PL375598A1 (en) 2002-07-18 2005-12-12 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
JP4644488B2 (en) 2002-07-19 2011-03-02 サイトス・バイオテクノロジー・アクチェンゲゼルシャフト Vaccine composition comprising amyloid beta 1-6 antigen array
WO2004084939A2 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag Hiv-peptide-carrier-conjugates
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
EP2266602A3 (en) 2004-11-01 2011-08-10 Novartis Vaccines and Diagnostics, Inc. Combination approaches for generating immune responses
PL1868642T3 (en) 2005-03-18 2013-10-31 Cytos Biotechnology Ag Cat allergen fusion proteins and uses thereof
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
EP2431468A1 (en) 2005-09-28 2012-03-21 Cytos Biotechnology AG Interleukin-1 conjugates and uses thereof
US20070184068A1 (en) 2005-12-14 2007-08-09 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
SI2032592T1 (en) 2006-06-12 2013-10-30 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
WO2010040023A2 (en) 2008-10-03 2010-04-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods and compositions for protein delivery
EP2376108B1 (en) 2008-12-09 2017-02-22 Pfizer Vaccines LLC IgE CH3 PEPTIDE VACCINE
IN2012DN00446A (en) 2009-07-30 2015-05-15 Pfizer Vaccines Llc
RU2538162C2 (en) 2009-09-03 2015-01-10 Пфайзер Вэксинс ЭлЭлСи Pcsk9 vaccine
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
WO2012122858A1 (en) * 2011-03-17 2012-09-20 中国科学院上海巴斯德研究所 Method for producing virus-like particle by using drosophila cell and applications thereof
EP2831225A1 (en) 2012-03-26 2015-02-04 The United States of America, As Represented by the Secretary, Dept. of Health & Human Services Office of Technology Transfer Delivery of packaged rna to mammalian cells
KR102467982B1 (en) 2013-12-16 2022-11-16 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
EP3089755A1 (en) 2014-01-03 2016-11-09 Fundacion Biofisica Bizkaia VLPs, METHODS FOR THEIR OBTENTION AND APPLICATIONS THEREOF
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
CN104450631A (en) * 2014-11-11 2015-03-25 中国人民解放军第四军医大学 Enterovirus EV71 type VP1 gene virus-like particle as well as preparation method and application thereof
CN105177031B (en) * 2015-06-12 2018-04-24 北京艺妙神州医疗科技有限公司 T cell of Chimeric antigen receptor modification and application thereof
WO2017179025A1 (en) 2016-04-15 2017-10-19 Alk-Abelló A/S Epitope polypeptides of ragweed pollen allergens
WO2019173438A1 (en) 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
CN119286871A (en) 2018-04-19 2025-01-10 查美特制药公司 Synthetic RIG-I-like receptor agonists
CN115279905A (en) 2019-10-23 2022-11-01 里珍纳龙药品有限公司 Synthetic RIG-I-like receptor agonists
EP4164681A1 (en) 2020-06-12 2023-04-19 GlaxoSmithKline Biologicals S.A. Bacterial immunization using nanoparticle vaccine
WO2023111826A1 (en) 2021-12-14 2023-06-22 Glaxosmithkline Biologicals Sa Bacterial immunization using qbeta hairpin nanoparticle constructs
CN118634321B (en) * 2024-06-28 2025-02-28 重庆医科大学附属第一医院 A preparation method for covalently coupling adjuvant and antigen of P24 virus-like particles

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991005864A1 (en) * 1989-10-13 1991-05-02 Connaught Laboratories Limited Production of genetically-engineered vaccines for aids and other retroviral diseases
WO1991007425A1 (en) * 1989-11-20 1991-05-30 Oncogen Limited Partnership Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
WO1992003537A1 (en) * 1990-08-15 1992-03-05 Therion Biologics Corporation Self-assembling replication defective hybrid virus particles
EP0508809A1 (en) * 1991-04-10 1992-10-14 British Bio-Technology Limited Proteinaceous lipid-containing particles
CA2098029A1 (en) * 1993-06-09 1994-12-10 Benjamin Rovinski Retrovirus-Like Particles Containing Modified Envelope Glycoproteins
WO1996005292A1 (en) * 1994-08-15 1996-02-22 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991005864A1 (en) * 1989-10-13 1991-05-02 Connaught Laboratories Limited Production of genetically-engineered vaccines for aids and other retroviral diseases
WO1991007425A1 (en) * 1989-11-20 1991-05-30 Oncogen Limited Partnership Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
WO1992003537A1 (en) * 1990-08-15 1992-03-05 Therion Biologics Corporation Self-assembling replication defective hybrid virus particles
EP0508809A1 (en) * 1991-04-10 1992-10-14 British Bio-Technology Limited Proteinaceous lipid-containing particles
CA2098029A1 (en) * 1993-06-09 1994-12-10 Benjamin Rovinski Retrovirus-Like Particles Containing Modified Envelope Glycoproteins
WO1996005292A1 (en) * 1994-08-15 1996-02-22 Connaught Laboratories Limited Antigenically-marked non-infectious retrovirus-like particles

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
M. MOTZ ET AL.: "Truncated versions of two major Epstein-Barr viral glycoproteins are secreted by recombinant chinese hamster ovary cells", GENE, vol. 58, 1987, pages 149 - 154, XP002027077 *
N. OSTERRIEDER ET AL.: "Expression of equine herpesvirus type 1 glycoprotein in E. coli and insect cells", J. GEN. VIROL., vol. 75, 1994, pages 2041 - 2046, XP002027076 *
N. OSTERRIEDER ET AL.: "Protection against EHV1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB)", VIROLOGY, vol. 208, 1995, pages 500 - 510, XP002027079 *
O. HAFFAR ET AL.: "Human immunodeficiency virus-like, non-replicating gag-env particles assemble in a recombinant vaccinia virus expression system", J. VIROL., vol. 64, no. 6, 1990, pages 2653 - 2659, XP002027078 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7348177B2 (en) 1998-12-31 2008-03-25 Novartis Vaccines And Diagnostics, Inc. Expression of HIV polypeptides and production of virus-like particles

Also Published As

Publication number Publication date
EP0817854A2 (en) 1998-01-14
CN1185811A (en) 1998-06-24
WO1996030523A2 (en) 1996-10-03

Similar Documents

Publication Publication Date Title
WO1996030523A3 (en) Antigen presentation system based on retrovirus-like particles
PT1012295E (en) ALFAVIRUS RNA REPLICATION SYSTEMS
AU642403B2 (en) Method for the use and synthesis of peptides
EP2042512A3 (en) Polynucleic acids and proteins from a porcine reproductive and respiratory syndrome virus and uses thereof
NO973250L (en) Preparations for delivery of antigens
WO1996033730A3 (en) Chemokine binding protein and methods of use therefor
EP1630229A3 (en) Melanoma antigens
EP1203817A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
AU4005295A (en) Compositions for the delivery of antigens
CA2190473A1 (en) Recombinant papilloma virus l1
EP2311952A3 (en) Antibodies to MRT-1 protein or fragments thereof
CA2220447A1 (en) Novel fusion protein recovery and purification methods
ATE207931T1 (en) DEVICE FOR PURIFYING AND MODIFYING PEPTIDES
AU7582594A (en) Recombinantly produced human membrane cofactor protein (MCP)
WO1999036568A3 (en) Method for identifying t-cell stimulating protein fragments
AU3772289A (en) Endotoxin binding protein and uses thereof
EP1304381A3 (en) Process for producing hydrophobic polypeptides, proteins or peptides
WO1996007739A3 (en) Interleukin-1 type 3 receptors
WO1997044054A3 (en) Type-2 chemokine binding proteins and methods of use therefor
DE69128039D1 (en) ALLERGENS FROM RYE SPOOLS
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
AU1041397A (en) Antigenic protein originating in malassezia
GR1002482B (en) New polymer membranes prepared from polysulfone and polyimide blends for the separation of industrial gas mixtures.
AU3384495A (en) Or-1 on orphan receptor belonging to the nuclear receptor family
DK0852623T3 (en) Nucleic acid molecules encoding proteins that mediate the adhesion of Neisseria cells to human cells

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96194306.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): BR CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996911989

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1998 930672

Country of ref document: US

Date of ref document: 19980102

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1996911989

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1996911989

Country of ref document: EP